Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics Closes on Public Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Complete Genomics announced today that it has closed its public offering of more than 6.3 million shares of its common stock at $12.50 per share.

The total number of shares sold includes 825,000 shares purchased by the offering's underwriters at $12.50 per share to cover over-allotments. The Mountain View, Calif., company had previously said that with the exercise of the over-allotment option, the net proceeds from the offering would be about $73.8 million.

Jefferies and UBS Investment Bank were joint book-running managers, while Baird and Cowen served as co-managers for the offering.

In a filing with the US Securities and Exchange Commission last month, Complete Genomics said that about $20 million of the net proceeds will be used to expand its sequencing and computing capacity in its facilities in Mountain View and Santa Clara, Calif. About $15 million will go toward further development of its sequencing technology and services, and $15 million will be used for sales and marketing activities.

The remainder of the net proceeds will go toward working capital and general corporate purposes.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.